Malignant fiberous hysteo sarcoma.

It was what one of the Kennedy kids had - and htey amputated his leg.

If the cancer does spread, it does show up in thelungs - as hers did.

It's in the lymph glands now.

I probably won't have access to a computer until I get back from winter break.

Osteosarcoma/Malignant Fibrous Histiocytoma of Bone Metastatic Osteosarcoma Treatment may be one of the following: Chemotherapy followed by surgery to remove the cancer followed by adjuvant chemotherapy. Surgery to remove the cancer followed by adjuvant chemotherapy. Surgery often includes removal of cancer that has spread to the lungs.

Recurrent Osteosarcoma Treatment depends on where the cancer recurred, what kind of treatment was given before, as well as other factors. A clinical trial may be a reasonable treatment option. If the cancer has come back only in the lungs, treatment may be surgery to remove the cancer in the lungs with or without chemotherapy. If the cancer has come back in other places besides the lungs, treatment may be combination chemotherapy. Clinical trials are evaluating new chemotherapy drugs.

http://www.emedicine.com/radio/topic420.htm

http://www.acor.org/cnet/62698.html Up to 20% of patients will have radiographically detectable metastases at diagnosis, with the lung being the most common site.[33] The prognosis for patients with metastatic disease appears to be determined largely by the site(s) and number of metastases and surgical resectability of the metastatic disease.[6][33][34][35] Patients who have complete surgical ablation of the primary and metastatic tumor (when confined to the lung) following chemotherapy may attain long-term survival, although overall event-free survival remains about 20% to 30% for patients with metastatic disease at diagnosis.[6][31][33][36] Prognosis appears more favorable for patients with unilateral rather than bilateral pulmonary metastases, and for patients with fewer nodules compared to patients with many nodules.[6][34] The degree of necrosis in the primary tumor after induction chemotherapy remains prognostic in metastatic osteosarcoma.[18] Patients with multifocal osteosarcoma (more than 1 bone lesion at diagnosis) have a poor prognosis.[37]

Malignant fibrous histiocytoma of bone (MFH) is generally treated according to osteosarcoma protocols, and the outcome for patients with resectable MFH receiving cisplatin and doxorubicin is similar to the outcome for patients with osteosarcoma.[38] As with osteosarcoma, patients with a good histological response had a longer survival than those with a poor response.[39]

Aggressive management, including surgical removal of primary and/or metastatic disease at the time of diagnosis or after intensive multiagent regimens, is necessary. All patients should receive intensive multiagent chemotherapy whether or not the primary and metastatic lesions are surgically resectable. Information about ongoing clinical trials is available from the NCI Web site.

Treatment options that are accepted approaches include the following:

Preoperative chemotherapy followed by surgical ablation of the primary tumor and resection of metastatic disease. This is followed by postoperative combination chemotherapy. The chemotherapeutic regimens utilized include high-dose methotrexate, doxorubicin, cyclophosphamide, cisplatin, high-dose ifosfamide (17.5 g/m2), etoposide, and carboplatin.[6] Surgical ablation of the primary tumor and metastases, where possible, followed by combination chemotherapy. The chemotherapeutic regimens utilized in the treatment of metastatic osteosarcoma include high-dose methotrexate, doxorubicin, cyclophosphamide, cisplatin, ifosfamide, etoposide, and carboplatin. []

There's more there about the prognosis with mets or recurrence to the bone, since you mention she uses a cane.